Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Thermo Fisher Scientific Inc (NYSE: TMO) closed at $488.12 in the last session, down -0.07% from day before closing price of $488.48. In other words, the price has decreased by -$0.07 from its previous closing price. On the day, 1.29 million shares were traded. TMO stock price reached its highest trading level at $490.98 during the session, while it also had its lowest trading level at $483.01.
Ratios:
We take a closer look at TMO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 28.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.87. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.65.
Scotiabank Upgraded its Sector Perform to Sector Outperform on July 11, 2025, while the target price for the stock was maintained at $590.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when CASPER MARC N sold 10,000 shares for $500.96 per share. The transaction valued at 5,009,586 led to the insider holds 115,174 shares of the business.
CASPER MARC N bought 10,000 shares of TMO for $5,009,588 on Aug 22 ’25. On Aug 20 ’25, another insider, CASPER MARC N, who serves as the Chairman & CEO of the company, sold 295 shares for $500.04 each. As a result, the insider received 147,512 and left with 115,174 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMO now has a Market Capitalization of 184319967232 and an Enterprise Value of 213250031616. As of this moment, Thermo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.25, and their Forward P/E ratio for the next fiscal year is 20.01. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 3.65. Its current Enterprise Value per Revenue stands at 4.935 whereas that against EBITDA is 19.713.
Stock Price History:
The Beta on a monthly basis for TMO is 0.76, which has changed by -0.20200104 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, TMO has reached a high of $627.88, while it has fallen to a 52-week low of $385.46. The 50-Day Moving Average of the stock is 9.03%, while the 200-Day Moving Average is calculated to be 0.99%.
Shares Statistics:
According to the various share statistics, TMO traded on average about 2.69M shares per day over the past 3-months and 1837850 shares per day over the past 10 days. A total of 377.61M shares are outstanding, with a floating share count of 376.99M. Insiders hold about 0.17% of the company’s shares, while institutions hold 90.77% stake in the company. Shares short for TMO as of 1755216000 were 3821685 with a Short Ratio of 1.42, compared to 1752537600 on 3830421. Therefore, it implies a Short% of Shares Outstanding of 3821685 and a Short% of Float of 1.01.
Dividends & Splits
The forward annual dividend rate for TMO is 1.64, which was 1.64 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.0033573534The stock’s 5-year Average Dividend Yield is 0.23. The current Payout Ratio is 9.43% for TMO, which recently paid a dividend on 2025-06-13 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 1996-06-06 when the company split stock in a 3:2 ratio.
Earnings Estimates
The current market rating for Thermo Fisher Scientific Inc (TMO) reflects the collective analysis of 21.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $6.49, with high estimates of $6.66 and low estimates of $6.22.
Analysts are recommending an EPS of between $22.62 and $22.29 for the fiscal current year, implying an average EPS of $22.49. EPS for the following year is $24.45, with 27.0 analysts recommending between $25.87 and $23.76.
Revenue Estimates
According to 18 analysts, the current quarter’s revenue is expected to be $10.9B. It ranges from a high estimate of $11B to a low estimate of $10.85B. As of the current estimate, Thermo Fisher Scientific Inc’s year-ago sales were $10.6BFor the next quarter, 18 analysts are estimating revenue of $11.75B. There is a high estimate of $11.94B for the next quarter, whereas the lowest estimate is $11.5B.
A total of 25 analysts have provided revenue estimates for TMO’s current fiscal year. The highest revenue estimate was $44.05B, while the lowest revenue estimate was $43.6B, resulting in an average revenue estimate of $43.87B. In the same quarter a year ago, actual revenue was $42.88BBased on 25 analysts’ estimates, the company’s revenue will be $45.94B in the next fiscal year. The high estimate is $47.58B and the low estimate is $45.24B.
